利妥昔单抗在抗中性粒细胞胞质抗体相关性血管炎患者中的药代动力学与临床结局
基于RTX in AAV试验中89例接受足量利妥昔单抗(每周375 mg/m²×4次)的ANCA相关性血管炎患者,在2、4、8、16、24周定量血清利妥昔单抗并计算梯形曲线下面积。结果显示药代动力学变异大,主要决定因素为性别和新诊断,未观察到药代动力学与临床结局的相关性。
要点
- 男性及新诊断患者利妥昔单抗血清水平显著较低。
- 药代动力学主要决定因素为性别和新诊断。
- 利妥昔单抗水平与6个月完全缓解及复发时间无显著关联。
核心结论
- 尽管采用基于体表面积的给药方案,ANCA相关性血管炎患者利妥昔单抗药代动力学变异很大,主要决定因素为性别和新诊断。
- 未观察到利妥昔单抗药代动力学与临床结局之间的任何相关关联。
- 监测血清利妥昔单抗水平在ANCA相关性血管炎中似乎没有临床用处。
研究设计与样本
- 研究纳入RTX in AAV试验中89例接受足量利妥昔单抗(每周四次输注375 mg/m²)的患者。
- 在2、4、8、16和24周定量利妥昔单抗,并通过计算梯形曲线下面积进行汇总。
主要发现
- 男性患者及新诊断患者的利妥昔单抗血清水平显著较低。
- 利妥昔单抗血清水平与体表面积、基线B细胞计数及疾病活动度呈负相关。
- 多因素分析中,利妥昔单抗药代动力学的主要决定因素为性别和新诊断。
- 第6个月达到完全缓解的患者与未达到完全缓解的患者利妥昔单抗水平相似。
- 利妥昔单抗水平较高的患者B细胞耗竭通常比利妥昔单抗水平较低的患者持续时间更长,但不同时间点的利妥昔单抗水平及曲线下面积与复发时间无关联。
临床怎么用
- 原文结论认为监测血清利妥昔单抗水平在ANCA相关性血管炎中似乎没有临床用处。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To study the determinants of the pharmacokinetics (PK) of rituximab (RTX) in patients with ANCA-associated vasculitis (AAV) and its association with clinical outcomes. METHODS: This study included data from 89 patients from the RTX in AAV trial who received the full dose of RTX (four weekly infusions of 375 mg/m2). RTX was quantified at weeks 2, 4, 8, 16 and 24, and summarized by computing the trapezoidal area under the curve. We explored potential determinants of the PK-RTX, and analysed its association with clinical outcomes: achievement of remission at 6 months, duration of B-cell depletion and time to relapse in patients who achieved complete remission. RESULTS: RTX serum levels were significantly lower in males and in newly diagnosed patients, and negatively correlated with body surface area, baseline B-cell count and degree of disease activity. In multivariate analyses, the main determinants of PK-RTX were sex and new diagnosis. Patients reaching complete remission at month 6 had similar RTX levels compared with patients who did not reach complete remission. Patients with higher RTX levels generally experienced longer B-cell depletion than patients with lower levels, but RTX levels at the different time points and area under the curve were not associated with time to relapse. CONCLUSION: Despite the body-surface-area-based dosing protocol, PK-RTX is highly variable among patients with AAV, its main determinants being sex and newly diagnosed disease. We did not observe any relevant association between PK-RTX and clinical outcomes. The monitoring of serum RTX levels does not seem clinically useful in AAV.
引用
- Cornec D, Kabat BF, Mills JR, et al. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (Oxford). 2018. PMID: 29340623. doi:10.1093/rheumatology/kex484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。